Wendy Young

Wendy Young, Ph.D. is a biotechnology, pharma and life science executive with more than 25 years of experience in the discovery and development of innovative drug discovery platforms and new medicines. She is currently an Executive Partner at MPM Capital focused on actively building and investing in innovative new companies in life sciences. Prior to joining MPM, she was the Senior Vice President at Genentech where she actively built and led the small molecule drug discovery organization. Under her leadership, more than 25 clinical candidates, in the areas of oncology, immunology, neurology, and anti-infectives, progressed into development. Additionally, Wendy led the BTK discovery program and is co-inventor of fenebrutinib which is currently in Phase 3 trials for multiple sclerosis. Prior to joining Genentech, Wendy held roles of increasing scientific leadership at Celera Genomics and Scios, a J&J company. Wendy is an inventor and/or author on more than 70 published patents and manuscripts. She was elected ACS National Chair of the Medicinal Chemistry Division (MEDI) in 2017, and currently serves as an associate editor of The Journal of Medicinal Chemistry. She received her Ph.D. from Princeton University, where she worked on folate analogs in collaboration with Eli Lilly, and Alimta® was an outcome of this collaboration.